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Abstract
To investigate the role of enhanced antigen presentation in dendritic cell (DC)–based immunotherapy. Here, we de-
scribe the development of a cell-penetrating mucin 1 (MUC1) antigen and its immunotherapeutic potential against
tumors. After animal groups received two immunizations of MUC1-MPA11P–pulsed DCs, we observed a marked
tumor regression compared with the mice treated with DCs alone or DCs pulsed with MUC1 peptide. We confirmed
themigration and homing of DCs in the popliteal lymph node usingmagnetic resonance imaging during the study. In
summary, enhanced antigen uptake using an MPA11P delivery molecule improves cell therapy.
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Introduction
Dendritic cells (DCs) play important roles as antigen-presenting cells
in innate and adaptive immunity, therefore they have become a primary
target for the development of immunotherapy against cancers [1,2].
Several studies have demonstrated the role of DCs in the induction
of antigen-specific immune responses against bacteria, viruses, and al-
lergens [3]. Furthermore, a DC regimen is capable of inducing specific
antitumor immune responses in mouse models [4,5] and humans [6].
In these studies, DCs were isolated and pulsed with exogenous tumor-
specific antigens. Afterward, the antigen-loaded DCs were transferred
to the hosts as cancer vaccines to enhance the immune responses against
tumor targets. To date, DC-based therapy has been used in clinical trials
for the potential treatment of a wide variety of cancers [7–12].
One of the most frequently tested tumor antigens in DC-based clini-
cal trials is mucin1 (MUC1). MUC1 is a large transmembrane glyco-
protein secreted on the apical surface of epithelial cells of mammary,
colon, and salivary tissues [13]. The extracellular domain of MUC1 is
composed of a repeating 20–amino acid sequence (GVTSAPDTR-
PAPGSTAPPAH)n, which is heavily O-glycosylated [14]. The tandem
repeated peptide contains several serine and threonine moieties where
glycosylation occurs. In neoplasic tissues, MUC1 is underglycosylated,
loses its polarity, and is overexpressed in most human epithelial cell ade-
nocarcinomas, including more than 90% of human breast [15–18],
colon [19,20], and pancreatic cancers [19–23]. Thus, it became an op-
timal target for therapy and imaging [24,25]. AlthoughMUC1-specific
antibodies and/or cytolytic T lymphocytes have been observed in some
patients, there is no consistent clinical response that demonstrates
that lymphocyte proliferation leads to the inhibition of cancer in pa-
tients [26–29]. Moreover, a recent review of DC vaccines in more than
1000 patients indicated that the overall response rate was just 8.9% [30].
Thus, the efficacy of DC vaccines still requires extensive research effort
for further treatment optimization. Particularly, the process of incu-
bating tumor peptide antigens with isolatedDCs in vitromust be exam-
ined carefully because the uptake of individual tumor antigens differs
widely from one type to another. In addition, it is unclear if there is a
marked difference in the uptake of tumor antigens between bona fide
versus isolated DCs. In a recent study, however, our group reported that
the latter did not uptake the fluorescence probe unless the myristoylated
polyarginine 11-mer peptide (MPA11P) delivery vehicle was used [31].
In line with this approach, a number of other works also focused on the
development of a reliable technique to deliver the antigens inside DCs
using penetratin [32] or Tat peptide [33]. In this study, we demonstrated
the benefit of enhanced antigen delivery in improving cell therapy.
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Materials and Methods
Reagents and Cell Lines
Murine breast cancer cell lines (mammary epithelial tumor cell line)
C57MG or the MUC1-transfected C57MG were generously provided
by Dr Sandra Gendler of the Mayo Clinic, Scottsdale, AZ. These cell
lines were cultured andmaintained inDulbeccomodified Eagle medium
(Mediatech, Manassas, VA) in the presence of 10% fetal calf serum
(FCS; Invitrogen, Carlsbad, CA), penicillin-streptomycin antibiotics
(Mediatech), and 10 μg/ml insulin (Sigma-Aldrich, St Louis, MO) at
37°C and 5% CO2 incubator. Chicken anti-EEA1 and Alexa 488–
labeled secondary antibodies were purchased from Invitrogen. Mouse
anti-MUC1 and Alexa 647–labeled secondary antibodies were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA).
MUC1.Tg Mice
A colony of MUC1 transgenic (MUC1.Tg) mice was maintained by
crossing MUC1.Tg mice obtained from Sandra Gendler (Mayo Clinic)
with a wild-type C57BL/6 strain (Jackson Laboratory, Bar Harbor,
ME). Themice were genotyped by a standard polymerase chain reaction
using DNA isolated from tail tips with the following primers: forward,
5′-CTTGCCAGCCATAGCACCAAG-3′; reverse, 5′-CTCCAC-
GTCGTGGACATTGATG-3′. After polymerase chain reaction ampli-
fication, the DNA product of each reaction was analyzed by size
fractionation through a 1% agarose gel. The size of the DNA product
from MUC1-positive mice corresponded with a 500-bp fragment.
MUC1 transgenic mice were maintained as hemizygous animals.
Animal experiments were carried out in accordance with the guidelines
provided by Vanderbilt University’s Institutional Animal Care and
Use Committee.
Synthetic MUC1 Peptides
The 30-mer antigen (APDTRPAPGSTAPPAHGVTSAPDTR-
PAPGS) with the most antigenic epitope recognized by anti–mucin
mAb and cytotoxic T cells and its counterpart that is covalently linked
to the delivery molecule, MPA11P (MPA11P (C14-(R)11)-APDTRPAP-
GSTAPPAHGVTSAPDTRPAPGS), were synthesized using con-
ventional fluoren-9-ylmethoxy carbonyl (Fmoc) chemistry [34,35].
After synthesis, the products were purified to 99% purity, as determined
by high-performance liquid chromatography and characterized by
matrix-assisted laser desorption and ionization time-of-flight mass
spectrometry. For the 30-mer antigen and the MPA11P-antigen, the
calculated molecular weights (MH+) 2837.87 and 4739.89 were found
to be 2837.08 and 4739.40, respectively.
Bone Marrow–Derived Dendritic Cells
DCs were isolated from the bone marrow of C57BL/6 mice as de-
scribed in the past [31]. Briefly, bone marrow precursors were flushed
out with RPMI from the femurs and tibias of mice and were subse-
quently processed into a single-cell suspension using a 70-μm mesh
strainer. Erythrocytes were lysed with 0.83% ammonium chloride with
2 minutes of incubation at room temperature. The cells were centri-
fuged for 5 minutes at 300g and washed twice in RPMI. After washing,
the cells were cultured in RPMI 1640 supplemented with 10% FCS,
50 μM2-mercaptoethanol, 1 mM sodium pyruvate, 100 U/ml penicil-
lin, 100 μg/ml streptomycin, 1000 U/ml recombinant granulocyte–
macrophage colony-stimulating factor, and 250 U/ml recombinant
interleukin 4 (both from PeproTech, Rocky Hill, NJ). On days 3 and
6 of the culture, nonadherent granulocytes and the B and T cells were
gently removed by suction from half of the media, after which fresh
media with cytokines were added. The released immature, nonadherent,
loosely adherent cells were collected on day 8, with typical morphologic
features of immature DCs. Cells in the day 8 culture were used as imma-
ture DCs. For most of the experiment, the immature DCs were pulsed
without any antigen, with theMUC1 peptide, or withMUC1-MPA11P
for 24 hours, and they were washed before experimental use.
T-cell Purification
T cells were purified from spleen and lymph nodes (LNs) of MUC1.
Tg mice with nylon wool (Wako Chemicals, Richmond, VA) column.
Briefly, spleen and LNs were removed from mice at the end of the ther-
apy and subsequently processed into a single-cell suspension using a
70-mmmesh strainer. The cell suspension was incubated in the column
filled with the sterile nylon wool and RPMImedium at 37°C for 1 hour
to adhere and trap B and other non–T cells to the nylon wool. Then,
T cells were collected from run-through medium of the column and
were used for the proliferation assay. The purity of the T cell was con-
firmed as greater than 95% by staining with a cell surface expression of
CD3 molecule with PE-conjugated anti–CD3e mAb (eBiosciences,
San Diego, CA) by FACS analysis.
T-cell Proliferation Assay
Carboxyfluorescein succinimidyl ester (CFSE) was used for the de-
tection of cell proliferation by FACS analysis. Purified T cells from
MUC1.Tg mice were used to determine the frequency of proliferat-
ing cells against subsequent antigen presentation of MUC1 peptide
by DCs. For staining T cells with CFSE (Invitrogen), T cells at 1 ×
106 cells/ml were incubated with 0.5 μM CFSE for 10 minutes at
37°C and 5% CO2. Staining was quenched by the addition of an
excess volume of ice-cold cell culture medium to the cell suspension
for 5 minutes. Day 8 cultures of DCs were pulsed with no antigen,
with MUC1 peptide antigen or MUC1-MPA11P. After the extensive
washing of DCs or T cells, those two populations were cocultured at
a 1:10 (DC/T) ratio for 5 days. The whole cells were further labeled
with mAbs for lineage markers, PE-conjugated anti-CD3e, antigen-
presenting cell–conjugated anti-CD4, and Cy7-conjugated anti-CD8a
(eBiosciences) for FACS analysis. Values from T cells incubated alone
without any DCs’ presence were referred as a background, whereas
T cells with mitogenic concanavalin A (ConA; Sigma-Aldrich) or
anti-CD3e activating antibody (eBiosciences) were referred as a sponta-
neous positive proliferation. Unstained cells were included in all experi-
ments and were applied for compensation setting of the flow cytometer.
The CD3+CD4+ or CD3+CD8+ T-cell proliferation was respectively
determined by gating on the lineage marker–positive subsets and CFSE
staining levels.
Immunotherapy
One million C57MG.MUC1 or C57MG (control) cells in 100-μl
serum-free Dulbecco modified Eagle medium were injected subcuta-
neously into the mammary fat pad as described previously [36]. At
8 to 10 days after the inoculation, small palpable tumors of approxi-
mately 0.4 cm were confirmed at the injection site, and the immu-
notherapy course was commenced as day 0. Tumor-bearing mice
were immunized subcutaneously in the footpads with PBS or 1 ×
106 unpulsed immature DCs or were prepulsed with 40 μM MUC1
peptides or 40 μMMUC1-MPA11P (n = 6, each group) at days 0 and
10 of the therapy course. At the conclusion of therapy on day 30, the
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mice were killed, after which LN, spleen, serum, and tumor were
cryopreserved to test the therapy profile as described below.
Tumor Measurement
Tumor volumes were measured with a high-resolution ultrasound
system (770 High-Resolution Imaging System; Visual Sonics, Toronto,
Ontario, Canada). The tumors were digitally sliced into 0.5-mm ultra-
sound images, which were applied to the three-dimensional volumetric
calculation by manually selecting a tumor area on each image in the
imaging system. During the course of therapy, tumor size was carefully
monitored and measured at 10-day intervals, with the methods men-
tioned above taking place from days 0 to 30. Once the tumor volume
reached 10% of body weight or larger than 2 cm, the mouse was with-
drawn from the therapy study and killed.
ELISA
The amount of cytokines in the blood sera was determined with in-
terferon γ (IFN-γ) and tumor necrosis factor α (TNF-α) ELISA kit
(eBiosciences). Briefly, 96-well microtiter plates were coated with cap-
ture Ab, either anti–IFN-γ (AN-18) or anti–TNF-α (TN3.19). Sample
sera were incubated in the coated plate in triplicate serial dilutions.
Biotin-conjugated Abs, either anti–IFN-γ (R4-6A2) or anti–TNF-α
(rabbit polyclonal), were used for detection. Finally, measurements of
the cytokines were determined with pretitrated avidin-HRP and tetra-
methylbenzidine (TBS) substrate solution and detected on a spectro-
photometer (Spectramax M5; Molecular Devices, Sunnyvale, CA) at
450 nm. As a standard for each cytokine amounts, mouse recombinant
IFN-γ or TNF-αwas used, and the value was referred for standard line.
Immunofluorescence and Immunohistochemistry
To determine the internalization of the MUC1 antigen inside
DCs, fixed and permeabilized DCs were stained for MUC1 and
EEA1 using anti-MUC1 antibody (1:500) and anti-EEA1 antibody
(1:500). After incubation with the corresponding Alexa-conjugated
secondary antibody (Alexa 647 for MUC1 and Alexa 488 for EEA1),
slides were mounted in Vectashield mounting medium (Vector Labora-
tories, Burlingame, CA). Dual-channel confocal microscopy was per-
formed using a Zeiss LSM510 (Carl Zeiss, Thornwood, NY).
For the detection of apoptotic cells in the tumor after therapy, we per-
formed a terminal deoxynucleotidyl transferase dUTPnick end labeling
(TUNEL) assay using a commercial kit (Millipore, Billerica,MA). Briefly,
tumors were cryopreserved and sectioned for immunohistochemistry on
termination of the therapy. Five-micrometer sections were fixed in cold
acetone for 10 minutes and incubated with 2.5% FCS containing PBS
for 30 minutes to block the nonspecific binding of the primary Abs to
the sample. The sections were washed three times with PBS, then sealed
with mounting medium (Vector Laboratories, Burlingame, CA). Finally,
the section was analyzed with a light microscope (Carl Zeiss Micro-
Imaging, Inc, Thornwood, NY). For the quantitative evaluation of
apoptotic cells in the tumor slides representative images of each tumor
slide were digitized and imported into Adobe Photoshop (version CS3;
Adobe Systems, San Jose, CA) in TIFF file format. The area of diamino-
benzidine staining was determined using the Color Range tool by select-
ing for the brown color of positive cells (RGB= 131/75/50; range = 100).
Pixel area was captured using the Record Measurements analysis func-
tion and calculated inMicrosoft Excel (Microsoft Corp, Redmond,WA).
Statistical analysis. The experimental data are reported asmean ± SD.
We compared the test groups using a paired Student’s t-test using Graph-
Pad software (GraphPad Software, La Jolla, CA). P values are two-tailed;
differences with a P value < .05 were considered statistically significant.
Results
Uptake of MUC1 Antigens
To confirm the tumor antigens were taken up by DCs, MUC1 anti-
gen and its counterpartMUC1-MPA11P derivative were incubatedwith
immatureDCs overnight. Then, the internalized antigens were detected
using confocal microscopy after staining the Triton X–treated cells with
anti-MUC1 and anti–endosomes antibodies. Figure 1 shows that both
MUC1 and MUC1-MPA11P were taken up inside DCs; albeit, the
concentration of the former seems to be inferior to the latter (n = 5).
This is not surprising because, according to the previous study, the
MPA11P delivery module could mediate the transfer of exogenous
materials inside DCs within 15 minutes of incubation [31].
Both MUC1- and MUC1-MPA11P–Laden DCs Induce
Remarkable CD8
+ T-cell Proliferation
Because the hallmark of DC therapy is the immune response mani-
fested by the proliferation of T cells, before the therapy started, we were
interested to learn whether T cells from MUC1 Tg mice could be in-
duced to proliferate on exposure to theMUC1 antigen–laden DCs. Pu-
rified T cells from MUC1.Tg mice were isolated and assessed for
frequency of proliferating cells against subsequent antigen presentation
ofMUC1 peptides byDCs. The T cells were first incubated with CFSE
and then they were cocultured with DCs that were pulsed with no anti-
gen, withMUC1, or withMUC1-MPA11P peptide antigens. T-cell pro-
liferation was assessed 5 days after stimulation by flow cytometric
analysis. Both MUC1- and MUC1-MPA11P–laden DCs induced
CD8+ T cells with similar strength (Figure 2). In contrast, no prolifer-
ation was observed for CD4+ T cells.
Delayed Tumor Growth in Mice Immunized with
MUC1-MPA11-P–Pulsed DC
We generated a mouse model of tumor tolerance by injection of the
C57MG-MUC1 tumor cells (kindly provided by Dr. Sandra Gendler)
in the fat pad of the MUC1 Tg mice. The animals were then divided
into four treatment groups comprised of untreated animals and animals
immunized with DCs alone, DCs pulsed with MUC1 peptide, or
MUC1-MPA11P.
The therapy commenced when the tumor size became palpable or
approximately 3 to 6 mm3. The mice were immunized in the footpads
with the doses of DCs as described. During the 30-day course of ther-
apy with two identical treatment doses administered 10 days apart
(Figure 3A), we observed that DCs pulsed with MUC1 peptide or
MUC1-MPA11P showed a marked delay in tumor growth by day 30,
whereas tumor growth demonstrated a significantly rapid pace among
untreated mice or mice immunized with DCs alone (Figure 3B). Fur-
thermore, mice immunized with MUC1-MPA11P–pulsed DCs exhib-
ited a marked suppression of tumor growth compared with other
treatment groups. These results suggest that enhanced antigen delivery
into DCs elicits significant antitumor immune responses against the
MUC1-expressing tumor in MUC1.Tg mice.
Enhanced Antigen Delivery Induced a Marked Increase
in Cytokine Level during Therapy
To assess the effects of the vaccine on the production of cytokines,
presumably from T cells, blood from each mouse were evaluated for the
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cytokine profiles associated with in vivo antitumor response. When the
therapy was completed on day 30, sera were analyzed for elevated serum
cytokine levels, particularly TNF-α and IFN-γ. A substantial difference
in cytokine levels was observed between the untreated and treated
groups. After the therapy, the level of cytokine production from the
former was significantly lower compared with the latter (Figure 4). No-
tably, the levels of TNF-α and IFN-γ in the serum of mice treated with
MUC1-MPA11P–pulsed DCs was higher compared with those in mice
treated with the MUC1-pulsed DCs.
Reduced Tumor Growth Is Associated with Increased
Apoptotic Death
To corroborate the retarded tumor growth with cell death, tumors
from each treatment group were dissected and subjected to immuno-
histochemistry to determine the presence of apoptotic cell death using
TUNEL assay. The degree of cell death in the tumor section was signifi-
cant when there was enhanced antigen delivery into DCs (Figure 5).
Under similar conditions, the tumor sections from mice treated with
MUC1-pulsed DCs failed to stain to the same degree. The ratio of ap-
optotic cells in tumor treated with MUC1-pulsed DCs versus MUC1-
MPA11P–pulsed DCs was 1:1.72.
Discussion
DCs are central to the priming and development of antigen-specific
T-cell immunity, which is necessary to elicit effective T-cell responses
to tumors. In this regard, the notion of using tumor antigen-pulsed
DCs with high specificity as tumor vaccines has been embraced as both
an ideal strategy and a burgeoning area of study in several ongoing
clinical trials. Despite significant advancements in DC-based therapy,
the approach remains challenging, especially with regard to developing
a simple yet robust method for activating the immune system against
cancer in the context of using tumor antigen–activated DCs. In this
work, we test the concept of enhanced antigen delivery in DC therapy
using the membrane-translating delivery system developed in our labo-
ratory [31,34]. This effort was pursued to answer one of the funda-
mental questions in DC therapy such as what would be the outcome
of therapy if a technique was available to guarantee antigen delivery?
Toward that goal, we developed the mouse model of tumor tolerance re-
ported previously [37] and tested the therapy usingMUC1 tumor antigen.
Before therapy, we confirmed that DCs could uptake theMUC1 anti-
gens developed in our laboratory. Figure 1 shows that both MUC1 and
MUC1-MPA11P were taken up inside DCs after an overnight incuba-
tion. However, the concentration of MUC1-MPA11P was apparently
higher than that of MUC1. By combining this observation with the
Figure 1. Confocal immunocytochemistry analysis the internalization of MUC1 antigens. Untreated DCs (A, B, C) and DCs treated with
MUC1 antigen (D, E, F) or MUC1-MPA11P (G, H, I) were fixed, permeablized, and stained with anti-MUC1 and anti-EEA1 antibodies followed
by fluorescently labeled secondary antibodies. MUC1 is pseudocolored in blue; EEA1, in green.
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onemade in the past [31], we hope that future therapy would not require
overnight incubation of the antigen with DC using a more efficient
means of delivering the antigen.
The 30-day in vivo therapy (Figure 3A, timeline) conducted on
tumor-bearing mice showed a significant regression in tumor growth
amongmice treated withMUC1-MPA11P–pulsed DCs compared with
other treatment groups, thus indicating the potential contribution of
MPA11P in inducing potent DCs. Altogether, these data suggest that
the appropriate delivery of antigens into DCs can induce potent anti-
tumor immunity. During therapy, the selected animals were chosen
for magnetic resonance imaging to confirm the effective migration of
DCs from the injection site to the lymph nodes. Toward that approach,
before adaptively transferring the cells to the treated mice, DCs were
pulsed briefly with iron nanoparticles using the previously described
protocol [38]. Twenty-four hours after injection, magnetic resonance
scans detected the decreased signal intensity in the popliteal lymph
nodes. This phenomenon is attributed to the homing of the iron nano-
particle-laden DCs (data not shown).
As shown in Figure 2, MUC1.Tg-derived CD8+ T cells incubated
with DCs pulsed with either MUC1 peptide or MUC1-MPA11P
showed proliferation. Interestingly, no effect was noted on the prolifera-
tion of CD4+ T cells in either group. The levels of CD8+ T-cell prolif-
erations, led by the MUC1-MPA11P–pulsed DCs, were not superior to
those of MUC1 peptide–pulsed DCs. Nevertheless, the in vivo ther-
apy study showed a marked slowdown in tumor growth among the
mice treated with MUC1-MPA11P–pulsed DCs compared with those
treated with MUC1 peptide–pulsed DCs. This observation suggests
the possibility that the number of CD8+ T cells proliferated by MUC1-
MPA11P–pulsedDCsmight have a higher number of activated/functional
cytotoxic T cells than those proliferated by MUC1 peptide–pulsed DCs.
Further, we cannot ignore the complexity of the factors engaged in the
in vivo environment, which promoted a slightly higher and persistent
antitumor immune response in the presence of MUC1-MPA11P–
pulsed DCs. In fact, immunohistochemical data indicated that the
level of tumor cell death in the MUC1-MPA11P treatment group is
apparently more obvious than in the group of mice treated with
MUC1-pulsed DCs (Figure 5). Semiquantitative analysis of the signal
associated with apoptotic cells showed that MPA11P-MUC1–pulsed
DCs induced apoptosis nearly two-fold more than MUC1-pulsed
DCs counterparts.
Figure 2. Induction of T-cell proliferation by MUC1 peptide or MUC1-MPA11P–pulsed DCs. MUC1.Tg mouse-derived purified T cells were
labeledwith 0.5 μMCFSE, and T-cell proliferationwas determined by flowcytometry. DCswere pulsed overnightwith no antigen,with 40μM
of MUC1 antigen, or with 40 μMMUC1-MPA11P. CFSE-labeled T cells and DCs were cocultured at a 1:10 ratio for 5 days. CD3
+CD4+ or CD3+
CD8+T-cell populations were gated and analyzed for the intensity of the CFSE by flow cytometry. For positive control, the CFSE–T cells were
pulsed with ConA; for negative control, the CFSE–T cells were cultured alone without the addition of cells or reagents for 5 days (not shown).
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It is worthwhile mentioning that although we observed a modest
delay in tumor growth within the group of animals treated with
MUC1-MPA11P–pulsed DCs compared with those treated with
the MUC1-pulsed DCs, that observation is credible. Here, we used
high-resolution ultrasound to measure tumor size, a method that is
much more precise than the caliper technique. Exact assessment of
the tumor volume is crucial in this study because tumor volume is
considered an indicator of therapeutic outcome. During the course of
this study, we confirmed an error made while using the manual cal-
iper approach to the volumetric measurement of tumors. The error
became evident when caliper-determined volumetric measurement
data began to exhibit overestimates at larger volumes as the size of
Figure 3. Inductionof antitumor immunitywithDC-based vaccines. (A) Timeline of the therapy. (B) DC-based therapy. Four groupsof age- and
sex-matched MUC1 Tg mice (n= 6, each) were inoculated with 1 × 106 C57MG-MUC1 cells subcutaneously in the fat pad area. Eight days
later, the untreatedmice (♦) or mice challengedwith DCs (•), DCs loaded with MUC1 tumor peptide antigens (▪), or DCs loaded with MUC1-
MPA11P (▴) vaccine regiments. The mice were treated with similar doses on day 10. (B) The tumor growth was monitored, measured, and
comparedwith the original size (day 0) using high-resolution ultrasound. Each point represents amean of sixmeasurements. We observed a
modest reduced tumor growth but with significant difference in the groups of mice treated with DC+MUC1-MPA11P compared with those
treated with DC + MUC1. *P < .05 in B (DC + MUC1-MPA11P vs DC + MUC1).
Figure 4. Analysis of the cytokine profiles in the serum of mice after a 30-day therapy by ELISA. Each filled circle corresponds to data from
one mouse. Vertical lines indicate mean value. Statistical analysis was performed using a paired Student’s t-test (*P = .0001). Cytokines
were induced by DC vaccines and shown as their concentrations (pg/ml). High levels of TNF-α and IFN-γwere observed in mice treated with
MUC1-MPA11P–pulsed DCs.
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the tumor increased compared with those done using the ultrasound
system (data not shown). Using the caliper technique, a tumor can be
measured externally; however, this method cannot measure tumors that
grow underneath the tissue. Furthermore, the various shapes of tumors
are not always ideal for applying the mathematical formulas.
Conclusions
In conclusion, we demonstrated the implication of enhanced antigen
delivery and imaging in DC-based therapy. These findings provide a
new avenue that might facilitate the implementation of protocols in
DC preparation for cancer immunotherapy and cancer vaccine develop-
ment. Notably, the MPA11P represents a promising delivery module for
carrying tumor antigens inside DCs. Finally, we envision a broad appli-
cation of our findings across many different types of cancers given that
MUC1 is overexpressed in various epithelial malignancies. Thus, it is a
suitable candidate for broadly applicable vaccine therapies.
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